SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

Novavax Reports Positive Preclinical Data On Influenza-COVID 19 Combination Vaccine

05/10/2021 06:09

10:02 AM EDT, 05/10/2021 (MT Newswires) -- Novavax (NVAX) announced Monday positive preclinical data on the combination of its quadrivalent seasonal flu vaccine NanoFlu and COVID-19 vaccine candidate NVX-CoV2373.

According to the company, combination vaccine demonstrated "positive immune responses" to both influenza and SARS-CoV-2, the coronavirus that causes the COVID-19 disease. Novavax said clinical studies on the combination vaccine are expected to start by the end of the year.

Novavax were down 8.1% in recent trading.

Price: 161.58, Change: -14.42, Percent Change: -8.19